Research News for Chester County- Page 6 of 9

Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial

April 7, 2024April 6, 2024 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …

Research

YPrime Survey Reveals Key Challenges in Oncology Trials, eCOA as a Solution

April 6, 2024April 5, 2024 - by Timothy Alexander

MALVERN, PA — In a groundbreaking survey released by YPrime, a leading provider of clinical trial software solutions, insights into the complexities of conducting oncology clinical trials have been brought …

Business / Research

Ocugen’s OCU410ST Advances in Clinical Trial for Stargardt Disease, Moving to Medium Dose Testing

April 3, 2024April 2, 2024 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a significant advancement in its ongoing clinical trial for Stargardt disease. The Data Safety and Monitoring Board (DSMB) for the …

Research

Annovis Bio’s Buntanetap Shows Promise in Early Alzheimer’s Disease Study

April 3, 2024April 2, 2024 - by Timothy Alexander

MALVERN, PA — In a significant development for Alzheimer’s Disease (AD) research, Annovis Bio, Inc. (NYSE: ANVS) has unveiled new data from a study indicating that buntanetap, an innovative oral …

Products and Services / Research

Annovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data Cleaning

March 24, 2024March 23, 2024 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biotech firm focused on developing novel treatments for neurodegenerative diseases, announced the successful completion of data cleaning for its pivotal phase …

Products and Services / Research

Ocugen’s Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon

March 18, 2024March 17, 2024 - by Timothy Alexander

MALVERN, PA — Ophthalmology is on the crest of a wave; a paradigm shift heralded by Ocugen, Inc (NASDAQ: OCGN) may be imminent. The Pennsylvania-based biopharmaceutical firm recently crossed a …

Products and Services / Research

Neuraptive Therapeutics Reports Encouraging 24-Week Data for NTX-001 in NEUROFUSE Study

February 28, 2024February 27, 2024 - by Timothy Alexander

WAYNE, PA — Neuraptive Therapeutics, Inc. has unveiled compelling 24-week data from its ongoing NEUROFUSE study on NTX-001, bolstering the product’s status after the positive proof of concept results based …

Products and Services / Research

Promising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIs

February 27, 2024February 26, 2024 - by Timothy Alexander

MALVERN, PA — Venatorx Pharmaceuticals, Melinta Therapeutics LLC, and the Menarini Group recently celebrated a significant medical breakthrough with the publication of the CERTAIN-1 Phase 3 clinical study results in …

Regional / Research

Cutting-Edge Study Connects Gut Health to Aging – New Routes for Chronic Illness Management?

February 25, 2024February 25, 2024 - by Timothy Alexander

PHILADELPHIA, PA — The Wistar Institute’s associate professor, Dr. Mohamed Abdel-Mohsen, and his team, recently made a ground-breaking discovery, published in the Microbiome. They unveiled a link between viral damage …

Products and Services / Research

Ocugen Achieves Clinical Milestone in Stargardt Disease Treatment

February 25, 2024February 25, 2024 - by Timothy Alexander

MALVERN, PA — In a promising development for the treatment of Stargardt disease, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company based in Chester County, Pennsylvania, has announced the completion of …